We are live on
!
Find out more
MFM
MHR Fund Management Portfolio holdings
AUM
$1.37B
1-Year Est. Return
68.35%
This Fund
S&P 500
This Quarter
Est. Return
+14.25%
1 Year Est. Return
+68.35%
3 Year Est. Return
+194.55%
5 Year Est. Return
+128.05%
10 Year Est. Return
+308.92%
AUM
$816M
AUM Growth
+$104M
(+15%)
Cap. Flow
+$52.2M
Cap. Flow
% of AUM
6.4%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
1
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$52.2M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 36.5% |
| 2 | Technology | 31.62% |
| 3 | Industrials | 13.18% |
| 4 | Healthcare | 11.23% |
| 5 | Financials | 7.47% |
Similar funds
ICM
SOS
EFG
PP
RI
HPC
AF
KRS
MHR Fund Management's Q3 2023 Portfolio in Review
As of Q3 2023, MHR Fund Management held 10 positions worth $816M, up 15% from $711M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
MHR Fund Management deployed $52.2M of net new capital in Q3 2023, adding to 1 existing holding.
By sector, the portfolio is most concentrated in Communication Services at 36% of assets, down from 44% a quarter earlier, followed by Technology and Industrials.
- MHR Fund Management added most to Iovance Biotherapeutics in Q3 2023, an estimated $52.2M increase.
- MHR Fund Management's ten largest holdings make up 100% of its $816M portfolio in Q3 2023.
- MHR Fund Management opened 0 new positions and closed 0 in Q3 2023.
- MHR Fund Management's portfolio value rose 15% quarter-over-quarter to $816M.
Based on MHR Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.